Cetaphil: The Texas Cleanser That Outlasted Its Owners

The label on Cetaphil Gentle Skin Cleanser gives two methods. With water, massage it into the skin and rinse it away. The less familiar method uses no water: apply a generous amount, rub gently, then wipe away the excess with a soft cloth and leave a thin film behind.

It comes out of the pump as a soft, milky cream with no fragrance and almost no foam. It does not scrub, cool the skin or leave a squeaky finish. When you are done, your face is supposed to feel much as it did before, minus the day.

Cetaphil turns up in family bathrooms, gym bags, pharmacies, clinics and student flats. Someone might first meet it as a teenager, find it beside a parent’s sink, or hear about it from a dermatologist trying to simplify a routine that has got out of hand.

People often first use Cetaphil when skincare has become a problem: the usual face wash starts stinging, the skin feels tight after washing, or too many active products have turned every step into a test. They want to get the skin clean without making it feel worse.

The beauty aisle is now full of low-foam cream cleansers and fragrance-free formulas promising to respect the moisture barrier. Gentle, soothing, hydrating, non-stripping: these words appear at nearly every price point, so a cleanser that skips the squeaky finish barely registers as unusual.

Cetaphil originated before this vocabulary became standard. For most of the twentieth century, lather was how people saw cleansing happen. Foam built up between the hands and spread across the face. Fragrance suggested that oil and dirt had been replaced with something cleaner. Tightness afterward read as proof that nothing remained. Gentle Skin Cleanser gave almost none of those signals, so users judged it by how their skin felt afterward.

The wipe-off directions made the same point. Cetaphil treated the remaining film as part of the intended finish, removing oil and residue without leaving the skin tight.

The same cleanser could sit beside acne treatment in one bathroom, baby products in another and a rich body cream in a third. It could be used on the face or body, with water or without, and fitted into routines that were already in place.

The formula changed far less often than the companies that owned it. Over the next eight decades, Cetaphil passed through mergers, sales and a joint venture while remaining a simple cream cleanser used at the sink.

1947: The Pharmacist Whose Name Was Lost

Most skincare brands build their history around a named founder, a doctor or chemist preserved in portraits and repeated origin stories. Cetaphil remembers the product and has more or less forgotten the person.

The official story says a pharmacist in Texas developed a cleansing lotion in 1947 for patients with sensitive skin. Nobody preserved his name, the city, the pharmacy or the first label. What survived is the formula and what it was for.

Called Cetaphil Cleansing Lotion, it had eight ingredients, no added fragrance and no soap. It could be rinsed with water or applied dry and wiped away. Calling it a lotion rather than a face wash was accurate. It was creamy and spreadable, closer to an emulsion than a bar of soap, and never needed to foam to work.

Its corporate home is easier to trace than its inventor. Cetaphil belonged to the Texas Pharmacal Company of San Antonio, founded in 1938 as part of an early wave of American businesses built around dermatology. The company made products for skin and scalp, including emollient bases that pharmacists could use directly or compound medicines into.

Such products had different priorities from ordinary cosmetics. They had to remain stable and predictable on skin that might already be irritated or undergoing treatment, whether or not they smelled luxurious. The trademark record reflects that orientation. Texas Pharmacal filed the Cetaphil mark in the US in 1962; the registration issued in 1963 and covered preparations for dermatosis, skin and scalp emollients, and vehicles for compounding medicine. Cetaphil began closer to the dispensary than the dressing table.

Canada was part of the story early. Texas Pharmacal applied for the Cetaphil trademark there in May 1960, more than two years before its US filing. The Canadian record says the mark had been made known there since 1953 and used there since November 1954. Cetaphil was crossing a border long before it acquired the machinery of a global company.

Records disagree about the launch date. Cetaphil’s own materials give 1947 as the year the lotion was created and launched, while the trademark filing records the name’s first commercial use in February 1950. The gap is unexplained and may reflect local use before the product entered wider trade. As patients used it, pharmacists restocked it and doctors recommended it, the formula became better known than the man who made it.

The short ingredient list did not mean clean beauty in the modern sense. That category did not yet exist. The original formula included ingredients that later became controversial, including sodium lauryl sulfate and parabens. Its simplicity was functional rather than ideological: each ingredient cleansed, preserved, stabilised or helped the lotion spread, while fragrance was omitted as an unnecessary variable for already uncomfortable skin.

The formula would eventually be dissected by beauty editors, defended by lifelong users and copied by store brands. Its original purpose remained simpler: washing can become uncomfortable when the skin is already irritated.

When Lather Was Proof

For most of the twentieth century, cleansers were expected to show their work through foam. Rub a wet bar of soap between your hands, spread the lather across your face and rinse it toward the drain. What remains is skin that feels bare and tight, sometimes almost squeaky, and that tightness read as proof that nothing was left behind.

Gentle Skin Cleanser was designed against those expectations. The thin cream made little lather and, in its dry method, ended with a cloth rather than a rinse. Users had to accept that a cleanser could work without making the face feel dramatically different afterward.

The chemistry explains why foam was never the point. Sebum, sunscreen, makeup and everyday residue do not dissolve in water alone. Cleansers use surfactants, molecules attracted at one end to water and at the other to oil, to surround oily material and help carry it away.

Foam is largely a byproduct of air, water and movement. A product can lather heavily without cleaning especially well, or produce almost nothing while still lifting oil and residue. The skin’s outer layer contains lipids that slow water loss and protect against irritants, so cleansing has to balance two tasks: remove oil and residue without leaving the skin tight and dry.

Ordinary soap is more alkaline than the skin and often strips more aggressively. Synthetic detergents gave formulators a way to clean closer to the skin’s natural pH and better control the after-feel.

Cetaphil’s original cleanser used sodium lauryl sulfate rather than ordinary soap. Its eight ingredients were water, cetyl alcohol, propylene glycol, sodium lauryl sulfate, stearyl alcohol and three parabens.

Sodium lauryl sulfate later became one of the most criticised ingredients in sensitive skincare, but a finished cleanser cannot be judged from one ingredient alone. Old Cetaphil produced little foam and felt unlike many other products using the same surfactant.

Cetyl and stearyl alcohol, despite their names, are waxy fatty alcohols that gave the lotion its creamy texture. Propylene glycol helped retain water, while the parabens preserved a water-based formula. Cetyl alcohol also supplied half the brand’s name: “Cet” came from cetyl alcohol, while “phil” suggested love or affinity.

From San Antonio to a Swiss Food Company

Texas Pharmacal operated from San Antonio, specialising in dermatology when skincare still sat somewhere between medicine, pharmacy compounding, personal care and cosmetics. Some products could be prescribed or recommended directly; others served as bases into which pharmacists compounded medicines.

Cetaphil fitted naturally into that business. It did not depend on a fashionable ingredient or elaborate advertising concept. A physician, pharmacist or patient could understand it as a soap-free cleansing lotion for skin that did not respond well to ordinary washing.

During the 1960s, Warner-Lambert acquired Texas Pharmacal as part of an expansion into specialist healthcare businesses. A later Federal Trade Commission filing lists Cetaphil Lotion alongside bath oils, creams and other emollients distributed largely through dermatologists. The product depended on professional recommendation rather than beauty-counter attention.

Alcon had begun in Fort Worth in 1945 as a small pharmacy founded by Robert Alexander and William Conner, its name formed from the opening sounds of their surnames. It grew from preparing sterile eye-care products into an international ophthalmology company making medicines and equipment.

Nestlé bought Alcon in 1977 as part of a push beyond food and beverages. The Swiss group had already taken a large stake in L’Oréal and was building interests in pharmaceuticals, medical products and health. Two years later, Alcon bought Texas Pharmacal from Warner-Lambert. Cetaphil had entered Nestlé through an eye-care subsidiary and now sat under the same owner as Nescafé, KitKat and infant formula.

Nestlé wanted healthcare businesses that combined scientific expertise with access to large markets. Alcon sold both professional medical products and products people used at home. Texas Pharmacal offered a similar structure in dermatology, with specialist credibility attached to repeat-purchase consumer products.

Alcon renamed Texas Pharmacal Dermatological Products of Texas, or DPT, and consolidated parts of its North American dermatology operations in San Antonio. Trademark ownership moved from Texas Pharmacal to Alcon Laboratories in 1979, then to Alcon’s Swiss pharmaceutical company in 1982.

Nestlé and L’Oréal Build Galderma

Nestlé entered dermatology through pharmaceuticals and acquisitions. Alongside Texas Pharmacal, Alcon owned Owen Laboratories, a Dallas dermatology company founded in 1961 and acquired eleven years later.

L’Oréal approached the field through beauty and biology. By the late 1970s, after decades studying hair, skin and cosmetic chemistry, it wanted to move beyond the appearance of skin into treating skin disease. In 1979, it opened the International Dermatology Research Centre, known by its French initials CIRD, at Sophia Antipolis in southern France.

Nestlé had commercial dermatology products and American pharmaceutical infrastructure. L’Oréal had a research centre and deep knowledge of skin biology. In 1981, they combined those assets in Galderma, an equal joint venture devoted entirely to skin: healthy and diseased, medical and aesthetic, prescription and everyday.

The company initially focused on prescription dermatology, studying acne, inflammation, fungal infections and how active compounds behaved in the skin. In 1984, Galderma researchers discovered adapalene, a retinoid developed for acne. More than a decade of research and clinical development followed before it launched as Differin in 1995, becoming one of the company’s defining pharmaceutical products. Galderma’s first commercial operations began in 1986.

After Cetaphil joined Galderma, it played a different role in the same routine. It did not treat acne, eczema or rosacea and was not a substitute for medicine. Its role was daily cleansing and moisturising around those conditions without making an already difficult routine harder.

A dermatologist could prescribe one Galderma product and recommend Cetaphil for washing and moisturising around it: the medicine addressed the condition, while the cleanser sat in the bathroom twice a day.

Cetaphil did not join Galderma when the venture formed. Much of Alcon’s dermatology business initially remained outside the new company. From 1988, Galderma began taking over those operations as Alcon refocused on ophthalmology. The Cetaphil trademark moved to Galderma in January 1990, nearly nine years after Galderma was formed and four years after its first commercial operations began.

That year, management investors bought DPT from Alcon and developed it into DPT Laboratories. The manufacturer moved further into creams, lotions and semi-solid medicines for pharmaceutical customers. Cetaphil did not go with it.

Cetaphil had already become a North American staple before the transfer. By the 1980s, Galderma said, it was stocked by all major retailers across the region. Once it joined Galderma, the cleanser could follow the company’s dermatology business into other markets.

The expansion gathered pace through the 1990s. In 1998, Galderma opened markets in China, Mexico and Israel, acquired Darrow in Brazil and bought a dermatology portfolio in the Nordic countries. It was also investing in a new factory near Montreal. Not every new Galderma market received the full Cetaphil range at once, but the company now had sales and regulatory operations abroad. Nestlé’s 1998 report described Cetaphil cleansers and moisturisers as receiving an excellent response from dermatologists around the world.

Unlike prescription medicines, Cetaphil could enter a routine with no diagnosis attached: dry skin, uncomfortable treatment, a parent washing a child, or simply a preference for cream over soap. Prescription products are used for defined conditions and periods; a basic cleanser can stay in a routine for years.

L’Oréal understood how texture affects whether someone wants to use a product. A formula can be scientifically sound and still fail if it spreads badly, smells wrong or makes the routine feel like work. Nestlé understood international consumer distribution and, through Alcon, how to run a regulated healthcare business and manage relationships with medical professionals.

Galderma combined those capabilities around skin, eventually building a portfolio that stretched across medicines for acne and rosacea, injectable aesthetics through fillers, neuromodulators and biostimulators, and consumer skincare through Cetaphil and later other brands.

Galderma’s dermatologist relationships, pharmacy presence and international distribution gave Cetaphil reach while the product itself remained technically simple. Its restrained packaging made it look closer to clinical care than conventional beauty. The brand relied on recommendation and repeat use rather than fragrance, a botanical origin story or promises of dramatic transformation.

Corporate ownership does not automatically make a cleanser gentler, and a dermatologist’s recommendation does not guarantee that a formula suits everyone. The association still helped move Cetaphil from dermatologists to patients, from pharmacies into supermarkets, and from one family member to the next. It went mainstream without losing the appearance of a specialist product.

How Recommendation Became Distribution

Dermatologists often see people after ordinary skincare has become complicated: acne treatment has dried the face, cold weather has made washing uncomfortable, or fragrance and scrubbing have become difficult to tolerate. In those situations, the cleanser has a supporting role.

Gentle Skin Cleanser was not an acne medicine, eczema treatment or cure for sensitive skin. Its narrower task was to remove oil and residue without making an already difficult routine more uncomfortable.

The directions were simple: apply, rub gently, then rinse or wipe away; the cleanser was fragrance-free, soap-free, usable on face or body and available without a prescription.

People often first used Cetaphil during a drying treatment in adolescence, then kept using it after the treatment ended. The bottle also moved through families, from parents to children, between siblings, and eventually into the homes of people who had grown up with it.

Once recommended, Cetaphil could be replaced without another appointment. As distribution widened, it moved from pharmacies into supermarkets, large retailers and eventually online.

Packaging kept the brand recognisable as distribution widened. Bottles changed over time, but the visual language remained restrained: white plastic, blue lettering and touches of green. Pumps suited larger bottles kept by the sink, while smaller bottles travelled. The packaging fitted equally well in a dermatologist’s display, a pharmacy aisle or a supermarket.

“Dermatologist recommended” eventually became central to Cetaphil’s marketing. Such claims require context, including geography, survey population and time period, and a recommendation for the brand does not mean every product suits every person. The link was reinforced each time someone heard the name during a consultation and found the same bottle in an ordinary store.

By the 1990s, that reputation had reached beauty editors. In 1996, the first Allure Best of Beauty Awards recognised Cetaphil Gentle Skin Cleanser alongside prestige brands including Chanel, Crème de la Mer, Estée Lauder and Clinique. The award treated simplicity, accessibility and predictability as qualities worth celebrating without turning the cleanser into a luxury product.

Later coverage repeated the same themes: classic, staple, a product that stayed in bathrooms while more fashionable formulas came and went. People described using it since middle school, finding it in their mother’s bathroom, or continuing a dermatologist’s recommendation from years before. The relationship was measured in empty bottles and uneventful mornings.

Retailers sold creamy cleansers with labels inviting comparison to Cetaphil, evidence that the original had become a category reference.

That did not make the product universal. Some users found the old formula insufficient for heavy makeup or sunscreen. Others disliked the film it left behind. People with oily skin sometimes wanted more foam or a cleaner rinse.

Cetaphil’s strength was not solving every cleansing problem, but offering a familiar starting point for people who wanted less sensory intensity.

This made Cetaphil useful as routines grew more elaborate. By the 2000s and 2010s, people were stacking acids, retinoids, vitamin C, acne treatments, masks and devices. Cetaphil remained the uncomplicated cleansing step. People who first encountered it in a consultation could now buy it almost anywhere and keep it at home.

From One Cleanser to the Whole Bathroom

Once someone finds a face wash that feels comfortable, the next question is what to use afterward. Dry skin needs moisturiser. Daytime brings sun exposure. The body may need something richer than the face. Acne-prone skin can be oily and dry at once, particularly during treatment.

Galderma expanded Cetaphil into those needs. Moisturizing Lotion extended the cleanser’s logic into a lighter emulsion for face or body. Moisturizing Cream offered a denser texture for rougher, drier skin. One poured or pumped; the other held its shape in a tub. Customers could choose by texture without learning an entirely new system.

Similar bottles and labels made the cleanser, lotion and cream look related. The cleanser and lotion often came in pump bottles, while the cream came in a tub. Buying all three turned a single-product purchase into a set kept by the sink. Larger formats also changed how the products were used: a small facial moisturiser invites precision, while a large pump or tub is applied to hands, arms and legs and shared across a family.

The range expanded into baby care, body washes, sunscreens, day and night moisturisers, acne products and formulas organised around specific concerns.

Cetaphil then divided the range by specific needs. Very dry or eczema-prone skin needs something different from oily or blemish-prone skin, even when both groups describe themselves as sensitive.

In 2010, Galderma launched Restoraderm for eczema-prone skin, with cleansers and moisturisers focused on dryness and barrier comfort. In 2012, Dermacontrol launched across six countries to address a different contradiction: skin that produces excess oil or breaks out can still be sensitive or dry.

The portfolio now covered skin type, concern, age, body area and routine step. That gave shoppers more choice but made the logo a less reliable guide: a creamy cleanser, foaming wash, sunscreen, exfoliant and acne formula cannot share the same ingredients or sensory profile.

The branding makes the range look consistent, but the formulas still have to be considered separately. A moisturiser is judged largely by spread, hydration and long-term comfort. A sunscreen must deliver its labelled protection when applied correctly. Acne and exfoliating products have to treat a concern without causing more irritation.

The products were linked by a common claim: each was designed with sensitive skin in mind. A sunscreen provided protection, an acne cleanser addressed oil and blemishes, and a body cream made repeated moisturising easier.

Each product remained a separate decision, but a successful first experience made the next easier to trust. The cleanser led to the moisturiser, and the moisturiser opened the way into body care, baby products, sun protection and concern-led ranges.

Galderma’s international structure carried this expansion into new markets, but the range never became uniform. Product names, pack sizes, sunscreen filters, claims and availability varied by country. Some markets built a strong body-care business; others mainly knew Cetaphil as a facial cleanser.

Regulation shaped what could be said on labels, which sunscreen filters could be used and how products associated with conditions such as eczema or acne could be positioned. Ingredients and indications could differ even when the front of the bottle looked similar.

Cetaphil went global without becoming identical everywhere, so shoppers in Singapore, Britain or the US might recognise the brand instantly while seeing different assortments.

The broader portfolio also changed the economics of the business. A single cleanser builds loyalty, but a complete routine creates more points of contact: cleanser morning and night, moisturiser afterward, body lotion after bathing, sunscreen during the day, and baby care bringing the brand into another generation of the household.

By the early 2010s, Cetaphil sat inside a Galderma that had also grown in prescription dermatology and injectable aesthetics. It remained the most accessible part of the system. No consultation, injection or prescription stood between the customer and the shelf.

Cetaphil’s retail reach mattered as the relationship between Galderma’s owners became more complicated.

L’Oréal Leaves and Nestlé Sells

By 2014, Nestlé and L’Oréal each owned half of Galderma. Nestlé also held 29.4 percent of L’Oréal, making it one of the beauty company’s largest shareholders, just behind the Bettencourt Meyers family.

Nestlé had first invested in L’Oréal in 1974, before it bought Alcon, before Alcon acquired Texas Pharmacal and before Galderma existed. The shareholding became a long-term alliance between companies with different core businesses but overlapping interests in health, beauty and research. Galderma was the most substantial business that alliance produced.

Over thirty years, the joint venture had grown into an international company spanning prescription medicines, consumer skincare and injectable aesthetics. Cetaphil carried Galderma into homes that would never encounter its medicines or injectables.

By 2014, Nestlé was both a shareholder in L’Oréal and a 50 percent co-owner of Galderma. On 11 February, the companies announced how they would unwind those ties.

L’Oréal sold its 50 percent stake in Galderma to Nestlé, valuing the dermatology company at €3.1 billion, including €2.6 billion in equity value. The transaction formed part of a larger share exchange in which L’Oréal bought back 48.5 million of its own shares from Nestlé, representing eight percent of its capital.

Part of the payment came through the Galderma stake. Nestlé handed back 21.2 million L’Oréal shares in exchange for it, while L’Oréal paid another €3.4 billion in cash for the remaining 27.3 million shares and cancelled the entire block.

Afterward, Nestlé’s ownership of L’Oréal fell from 29.4 to 23.29 percent, while the Bettencourt Meyers family’s stake rose from 30.6 to 33.31 percent as the number of shares outstanding shrank. L’Oréal said it would now focus exclusively on beauty. Galderma’s prescription medicines and injectables sat outside that definition.

Nestlé viewed full ownership of Galderma as support for its strategy around nutrition, health and wellness. Galderma became the foundation of a wholly owned division called Nestlé Skin Health.

For Cetaphil, the deal did not alter its daily role. The cleanser remained in pharmacies and supermarkets, the lotion in its pump bottles and the cream in its tub.

Nestlé Skin Health combined consumer skincare, prescription dermatology, injectable aesthetics and professional skin-health services. They were all skin businesses, but they operated differently: prescription dermatology required trials, regulatory filings, medical affairs and physician relationships; injectable aesthetics depended on trained practitioners, devices and specialised education; consumer skincare travelled through ordinary retail channels.

Nestlé continued expanding the division. In 2016, Nestlé Skin Health acquired the company behind Proactiv. By 2017, the division employed more than 5,000 people across forty countries and generated about CHF 2.7 billion annually. Cetaphil remained one of its most visible consumer brands.

At the same time, Nestlé was reassessing its portfolio. Mark Schneider became chief executive in 2017, the first outsider to lead the company in nearly a century, and accelerated the review of businesses outside its strongest growth priorities.

Skin Health came under the same scrutiny, and in September 2018 Nestlé said it would explore strategic options for the division. Four years earlier, medical dermatology had been presented as an extension of health and wellness. Now prescription dermatology and aesthetics looked too distant from food, beverages and nutrition.

Cetaphil itself might have fitted comfortably inside a consumer-health company, but Nestlé evaluated Skin Health as an integrated division. Rather than separate the consumer brands from the prescription and aesthetics businesses, it sought a buyer for the whole operation.

In May 2019, Nestlé agreed to sell the division for CHF 10.2 billion to a consortium led by European private-equity firm EQT and including a subsidiary of the Abu Dhabi Investment Authority, PSP Investments and other institutional investors. The sale closed on 2 October.

Nestlé Skin Health disappeared as a corporate identity. The business revived the Galderma name and described itself as the world’s largest independent dermatology company.

Galderma was independent of Nestlé but owned by the investors who had bought it. EQT and its partners planned to grow the business and eventually exit through a sale or public listing.

Flemming Ørnskov, previously head of Shire, became chief executive. Galderma retained its three businesses: prescription dermatology, injectable aesthetics and consumer skincare.

By 2019, Cetaphil had become an investor-owned global brand. The formula had remained stable for generations, but shoppers were now scrutinising sulfates and parabens, seeking niacinamide and glycerin, and expecting sensitive-skincare brands to explain the moisture barrier. In 2021, Galderma reformulated the cleanser that had come to represent continuity.

The 2021 reformulation

On 22 September 2021, Galderma announced a large Cetaphil relaunch. Gentle Skin Cleanser, Daily Facial Cleanser, Moisturizing Lotion, Moisturizing Cream and Advanced Relief Lotion were reformulated, with new packaging, claims and a revised logo.

The original Gentle Skin Cleanser had used the same eight-ingredient formula for decades. Long-term users knew its thin, milky texture, minimal foam and the film left by the wipe-off method.

The new Gentle Skin Cleanser used ten ingredients: water, glycerin, cetearyl alcohol, panthenol, niacinamide, pantolactone, xanthan gum, sodium cocoyl isethionate, sodium benzoate and citric acid. Sodium lauryl sulfate, propylene glycol and the three parabens disappeared.

By 2021, sodium lauryl sulfate had become one of skincare’s most criticised surfactants, and parabens were not far behind, despite their long track record and continued approval within permitted limits. Shoppers were turning the bottle around before buying. Niacinamide, glycerin, hyaluronic acid and ceramides had entered everyday skincare vocabulary, and product reviews routinely debated surfactants, preservatives and barrier function.

“Gentle” no longer stood as a complete explanation. Brands were expected to describe how gentleness worked. The old formula relied on history and experience just as shoppers increasingly wanted recognisable mechanisms and ingredients. Many shoppers were also looking for formulas marketed without parabens, sulfates or animal-derived ingredients.

The revised list gave Galderma a new vocabulary for the product. Glycerin helped attract and retain water. Panthenol supported hydration and comfort. Niacinamide could be discussed through barrier function and texture. Sodium cocoyl isethionate replaced sodium lauryl sulfate as the main cleansing ingredient, while Galderma began describing the cleanser through micellar technology.

The product remained creamy, fragrance-free and low-foaming, and retained both methods of use: rinse with water, or wipe away the excess and leave a thin film.

Galderma changed almost every ingredient but retained the same basic use. It now described the cleanser through hydration, resilience and defence against five signs of sensitivity: dryness, irritation, roughness, tightness and a weakened moisture barrier.

The reformulation extended across the range. Niacinamide, panthenol and glycerin appeared in several major products, linking the portfolio through barrier-care claims rather than a shared minimalist formula.

Packaging changed too, though the blue-and-green identity remained. The logo became cleaner and the labels more structured. Colour coding distinguished skin types, while claims previously confined to supporting copy moved onto the front of the pack.

During 2021, the company announced sixteen new products, expanding the US portfolio to fifty-nine and entering mineral sun care, acne, rough skin, cracked skin, dark spots and uneven tone. The range was no longer led only by cleanser and moisturiser.

The rollout was uneven. Old and new formulas appeared on shelves simultaneously. Rollout dates differed by country and retailer. Online images did not always match what arrived. Shoppers compared ingredient lists to identify which version they had bought.

For customers who had questioned the old sulfates and parabens, the change looked overdue; for long-term users, “improved” was less straightforward.

A formula can perform better in company testing and feel worse on a particular face. Glycerin changes slip and after-feel. A different surfactant changes how a cleanser spreads and rinses. Niacinamide suits many people, but not everyone. Even a slight change in thickness becomes obvious to someone who has used the same cleanser for years.

Some customers preferred the new texture and ingredients, while others reported different foaming, residue or skin reactions and searched for remaining stock or similar store-brand formulas.

People who use skincare for pleasure may welcome novelty. People who use a cleanser because everything else has failed tend to be more cautious. For skin that accepted the old formula, dated could simply mean dependable.

Galderma stopped claiming that the cleanser retained the original recipe. Instead, it said the new product delivered the same kind of gentle results.

The current cleanser is a reformulation, not the pharmacist’s original lotion. It reflects current ingredients and ideas about the moisture barrier.

What survived from 1947 was simpler than any formula: a creamy, restrained cleanser for people who do not want washing to become another source of discomfort. The option to skip water remained, along with the idea that the skin’s condition afterward mattered as much as what had been removed.

Sales continued to grow. In 2023, Cetaphil exceeded US$1 billion in annual sales. The following year, Galderma went public, giving L’Oréal a route back into the company it had left a decade earlier.

A Billion-Dollar Brand

Cetaphil passed US$1 billion in annual net sales in 2023. The figure covered the global portfolio rather than the original cleanser alone.

A cleansing lotion from an unnamed pharmacist had become the flagship consumer brand of an international dermatology company. Around it sat moisturisers, body washes, baby products, sunscreens, acne care, brightening ranges, serums and products organised around dryness, redness, oiliness and visible ageing.

In 2023, Galderma introduced Healthy Renew in Brazil and the US, positioning purified peptides as a retinol alternative for sensitive skin. Cetaphil was entering a category filled with prestige serums, active ingredients and promises of renewal, far from the practical cleansing lotion that began the brand.

The company also introduced an AI skin-analysis tool. Users could upload a selfie, receive an assessment of visible concerns and get a suggested Cetaphil routine, based on what Galderma described as a database of 70,000 diverse skin images.

When the range consisted mainly of cleanser, lotion and cream, customers could choose by texture and routine step. With dozens of specialised products, shoppers needed help choosing between them. The AI tool was designed to guide that choice.

The growth did not require Cetaphil to move into luxury pricing or leave pharmacy and mass retail. It remained widely available consumer skincare inside a company also active in prescription medicines and medical aesthetics.

That growth strengthened the case for a public listing. The EQT-led consortium had bought Nestlé Skin Health in 2019 for CHF 10.2 billion, reorganised it under the Galderma name and invested across dermatological skincare, therapeutic dermatology and injectable aesthetics.

On 22 March 2024, Galderma began trading on the SIX Swiss Exchange under the ticker GALD. Shares were priced at CHF 53, the top of the announced range. Including the over-allotment option, roughly CHF 2.3 billion of shares were placed. It was Switzerland’s largest initial public offering since 2017 and one of Europe’s largest healthcare listings in years.

The investor consortium retained most of the company after the listing, while a minority of shares traded publicly. The listing gave Galderma a market valuation and gave its owners a way to reduce their stakes. It also gave L’Oréal a way back into the company.

L’Oréal Comes Back

In August 2024, L’Oréal announced that it would buy 10 percent of Galderma from the EQT-led consortium and its partners. L’Oréal’s later accounts put the cost at about €1.8 billion, almost exactly ten years after it had sold its original 50 percent stake.

L’Oréal bought a minority position in a public company. Nestlé was gone, Galderma had independent management and outside shareholders, and L’Oréal initially said it would not seek board representation.

The companies also agreed to pursue a scientific partnership. Galderma brought expertise across therapeutic dermatology, consumer skincare and medical aesthetics; L’Oréal brought skin biology and diagnostic technology. These were the same broad strengths that had supported Galderma’s creation in 1981, now joined through a minority shareholding rather than a joint venture.

Cetaphil was part of the attraction, but L’Oréal was also buying into Galderma’s aesthetics business. By 2024, Galderma had become one of the world’s largest injectable-aesthetics companies, with Restylane fillers, Sculptra biostimulation products and Dysport neuromodulators alongside prescription dermatology and consumer skincare.

The investment gave L’Oréal exposure to medical treatment, skin science and appearance without requiring it to acquire Galderma outright. Galderma gained a long-term shareholder with deep expertise in skin research and global beauty, while the private-equity consortium gained another route to reduce its position after the listing.

Sixteen months later, L’Oréal doubled its holding. On 8 December 2025, it announced an agreement to buy another 10 percent from the investor consortium. The deal closed on 10 February 2026 for €4.2 billion, bringing L’Oréal’s total stake to 20 percent.

L’Oréal had sold its entire 50 percent interest in 2014 at an equity value of €2.6 billion. Twelve years later, it paid €4.2 billion for an additional 10 percent. The figures are not directly comparable: Galderma in 2026 was a larger and substantially different company, with an expanded aesthetics business, new medicines, additional brands and a public valuation.

The second purchase gave L’Oréal greater influence. Galderma said it would consider nominating two non-independent directors representing L’Oréal, replacing members tied to the EQT-led consortium. L’Oréal described its 20 percent holding as giving it significant influence over the company.

The investor consortium that had bought Galderma from Nestlé dissolved its coordinated ownership arrangement, and by March 2026 Galderma reported an effective free float of 80 percent, with L’Oréal holding the remainder.

Galderma remained an independent public company. L’Oréal did not directly own Cetaphil or control Galderma as a subsidiary, and said it had no plans to increase its holding further. A 20 percent stake gave L’Oréal a meaningful share of Galderma’s results, influence over its long-term direction and the prospect of board representation. The beauty company that had helped create Galderma, sold its entire half and spent a decade outside the business had returned as its most important strategic shareholder.

Nestlé, meanwhile, remained absent, having left dermatology completely in 2019. The company had acquired Alcon, brought Cetaphil into its orbit, created Galderma with L’Oréal, bought L’Oréal out and assembled Nestlé Skin Health.

Nestlé concluded that prescription dermatology and aesthetics sat too far from its core in food, beverages and nutrition. L’Oréal reached the opposite conclusion. Beauty remained its centre, but medical aesthetics and dermatological science had moved close enough to justify billions of euros of investment.

Cetaphil changed hands because each owner valued a different part of the business. The original pharmacist made a cleanser for patients who found ordinary soap uncomfortable. Warner-Lambert and Alcon saw a dermatology product inside a pharmaceutical portfolio. Nestlé and L’Oréal used it to build a global dermatology company. Private equity saw an independent company ready for investment and a public listing. L’Oréal returned for access to skin science and medical aesthetics.

For customers, the ownership changes mattered only if they changed the product’s availability, formula or price. The bottle remained a cleanser used at the sink.

The current cleanser

Cetaphil’s history cannot predict how a formula will suit an individual person. Dermatologist recommendations, clinical studies and a long sales record all provide context, but they do not make a cleanser right for every skin.

Sensitive skin is not one skin type. It can be dry or oily, briefly uncomfortable or persistently reactive, shaped by climate, cleansing habits, prescribed treatment, fragrance, individual ingredients or the number of products layered into a routine. Two people can use the same cleanser and have opposite experiences.

Cetaphil was an early cleanser that did not depend on abundant foam, fragrance or post-wash tightness to signal that it worked. That idea is ordinary now. Modern cleansers promise not to strip, and skincare advice warns against confusing tightness with cleanliness.

Some people who loved the old cleanser never accepted the reformulation, while others find the current version easier to use. Cetaphil remains a reference point because retailers compare creamy cleansers to it and people still mention it when recommending uncomplicated drugstore routines.

It began as a cream cleanser for people who found ordinary washing uncomfortable. The company became much larger; that basic test has not changed.